ACE-IPF AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Trial Location:
Main Campus, Denver, CO
Principal Investigator:

Kevin Brown, MD

Trial Sponsor(s):

National Heart Blood and Lung Institute (NHLBI)

Trial Objective:

To test the safety and effectiveness of treatment with warfarin, compared to placebo in patients with idiopathic pulmonary fibrosis

Patient Groups:

  • 256 patients will enroll in the study from 22 centers in the United States.
  • 128 patients will receive warfarin and 128 will receive a placebo.

Visits:

  • Screening visit to determine eligibility
  • Study visits every 16 weeks for approximately 3 years
  • Post treatment safety follow up, up to 28 days after treatment discontinuation
Compensation:

Not Provided

Who Can Participate:

  • Male or female patients between 35 and 80 years of age (Females of childbearing potential must use a reliable method of contraception)
  • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  • Subjects must have progressed despite conventional therapy (standard of care)
  • Diffusion capacity (DLCO) greater than or equal to 35% of predicted value
Enrollment:

Completed and Research Published

Bookmark and Share